QLIFE Aktie

 

Qlife Holding AB ("Qlife" or the "Company") has entered into a non-binding letter of intent ("Letter of Intent") with Hipro Biotechnology Co., Ltd., registration no. 91130100794182204D, ("Hipro") regarding a potential merger in the form of a reverse takeover ("Transaction") of Hipro, a Chinese med-tech company. According to the Letter of Intent, Qlife will acquire Hipro and issue new shares to Hipro's shareholders, meaning that Hipro's shareholders will hold approximately 83.3 percent of the outstanding shares in Qlife after the Transaction. The purchase price for Hipro is based on a share...

Qlife Holding AB held its annual general meeting on 28 May 2025. At the meeting, the following resolutions were made. The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail. Income statements and balance sheets as well as allocation of the company's profit or loss The general meeting resolved to adopt the income statement and the balance sheet as well as the consolidated income statement and the consolidated balance sheet for the fiscal year of 2024. The meeting resolved, in...

Progress on all levels The full report is attached and can also be found here: https://qlifeholding.com/en/investors/finansiella-rapporter Financial summary – first quarter 2025 · Revenue in the period amounted to kSEK 110 (0). · EBITDA for the period amounted to kSEK –5,269 (–11,716 ), and net loss kSEK -6,120 (–8,351). · The total cash flow in the first quarter amounted to kSEK -8 (2,714 ). · Earnings per share before/after dilution for the quarter amounted to SEK -0.73 (-0.01), calculated on weighted average number of shares in the period. Significant events – first...

Qlife Holding AB's ("Qlife") Annual Report is available on Qlife's website: https://qlifeholding.com/en/investors/financial-reports The Annual Report can be downloaded from the website or ordered from Qlife, info@egoo.health. For further information, please contact: Thomas Warthoe, CEO Qlife Holding Email: tw@egoo.health Phone: +45-21 63 35 34...

Aktieägarna i Qlife Holding AB, org.nr 559224-8040, kallas till årsstämma den 28 maj 2025 kl. 11.00 i Moll Wendén Advokatbyrås lokaler på Stortorget 8 i Malmö. Rätt att delta och anmälan Den som önskar delta i stämman ska: · dels vara upptagen som aktieägare i den av Euroclear Sweden AB framställda aktieboken avseende förhållanden på avstämningsdagen som är den 20 maj 2025 · dels anmäla sig till stämman senast den 22 maj 2025. Anmälan görs per post till Qlife Holding AB, Årsstämma, Nellickevägen 22, 412 63 Göteborg eller per e-post till info@egoo.health. I anmälan bör uppges...

Qlife is positioned at the forefront of the fast-growing at-home diagnostics market, offering lab-grade biomarker testing with global potential. In light of recent additions to the Board of Directors, a successful capital raise, and regulatory clearance from UK authorities to begin clinical trials, the company is now announcing its upcoming roadmap. This roadmap outlines key growth areas with a strong focus on commercialization, regulatory milestones, and strategic partnerships. From expanding its presence in the Chinese Hospital-at-Home segment to pioneering immunodiagnostic testing for...

The Egoo Phe System, developed to measure phenylalanine (Phe) levels associated with the PKU condition, is now entering its final phase ahead of initial registration in the UK and submission to a Notified Body for self-testing approval by non-professional users in the UK, as well as under the IVDR for EU markets. The clinical trial will run for six months in the UK, after which the dossier will be submitted to the relevant UK authorities. As self-testing by non-professional users represents the highest classification for an In-Vitro Diagnostic (IVD) product, the application must also be...

Today, on 21 March 2025, an extraordinary general meeting was held in Qlife Holding AB. A summary of the adopted resolutions follows below. Election and remuneration of the board of directors The extraordinary general meeting resolved to re-elect Lars Staal Wegner and Mikael Persson as ordinary board members and to elect Flemming Pedersen, Jørgen Drejer and Jacob Glenting as new ordinary board members. It was furthermore resolved to elect Flemming Pedersen as new chairman of the board of directors. The extraordinary general meeting resolved that Flemming Pedersen, Jørgen Drejer and...

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURE The rights issue that was announced on 29 January 2025 (the “Rights Issue”) in Qlife Holding AB (publ) (“Qlife” or the “Company”) has been registered with the Swedish Companies Registration Office (Sw. Bolagsverket) and paid...

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURE Qlife Holding AB (publ) (“Qlife” or the “Company”) has completed the issue of shares with preferential rights for the Company's shareholders that was resolved by the Board of Directors on 29 January 2025 with the support of the...

Following a successful rights issue, Qlife has convened an extraordinary general meeting to expand its Board of Directors with three new members, each bringing extensive life science and operational expertise. This expansion of the Board of Directors lays the foundation for accelerated commercialization of the company's products. With approximately 91 percent subscription in the rights issue and a secured credit facility, Qlife has ensured financing for at least the next 12 months. The company is now able to solely focus on advancing its strategy to deliver lab-quality blood testing and AI-...

Qlife Holding AB, reg.no. 559224-8040 (the ”Company”), will hold an Extraordinary General Meeting on 21 March 2025 at. 10.00 at Moll Wendén Law Firm's office at Stortorget 8 in Malmö. The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail. Notification etc. Anyone wishing to participate at the meeting shall: · be listed as a shareholder in the share register maintained by Euroclear Sweden AB as of the record date, which is 13 March 2025, and · give notice of the intent to...

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURE On 29 January 2025, Qlife Holding AB (“Qlife” or the “Company”) announced a rights issue of approximately SEK 11.8 million (the “Rights Issue”). The subscription period of the Rights Issue ended on 25 February 2025. Today, Qlife...

Das Instrument 4HG0 SE0022574331 QLIFE HOLDING AB EQUITY wird ex Kapitalmassnahme gehandelt am 06.02.2025 The instrument 4HG0 SE0022574331 QLIFE HOLDING AB EQUITY is traded ex capital adjustment on 06.02.2025...

The CEO of Qlife Thomas Warthoe has been sanctioned by Finansinspektionen related to insider information. The sanction relates to an incident in February 2023 when Thomas Warthoe forwarded an email with details related to a rights issue. The e-mail was forwarded to Peter Warthoe, CSO of the company and Thomas' brother. Peter Warthoe had previously been part of Qlife management but was no longer part of the management at the time of the forwarding. The rights issue was made public later in February 2023. The information should not have been forwarded and Thomas Warthoe acknowledges his...

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURE Today, the Board of Directors in Qlife Holding AB (“Qlife” or the “Company”) has, with the authorisation granted from the annual general meeting held on 26 June 2024, resolved to carry out an issue of 5,883,817 shares with...

Qlife has been in discussions with a top-20 global Pharma company to explore opportunities for the sales, distribution, and marketing of the Egoo Health platform, as well as to advance a potential commercial collaboration. The parties have signed a letter of intent (LOI); however, due to the early stage of negotiations, they have agreed to keep the company's identity confidential. Qlife is actively pursuing a partnership strategy and, with recent advancements in the Egoo Health product lines, expects to establish one or more partnerships during 2025. These collaborations will focus on the...

The company is pleased to announce that Qlife, in collaboration with its strategic partner Hipro Biotechnology, has developed a new Egoo Health product platform, which is already CE-IVD-marked. As a result, sales can commence immediately in the EU. Qlife and Hipro Biotechnology have joined forces to introduce a jointly developed, CE-IVD-marked platform to the market. This new solution combines the best of Hipro's technology with Egoo Health's innovations. It is based on Hipro's already CE-IVD-marked Palm F product line, enhanced by Qlife's high-tech Egoo optics, plasma-filtration, expertise,...

The company has shifted its focus from research and development to becoming a sales-driven organization, emphasizing the distribution of its high-quality Egoo Health product platform in the rapidly expanding home diagnostics market. Qlife has successfully sold its RUO-approved Egoo Phenylalanine (Phe) system in seven countries and is currently conducting studies in the UK and Denmark to prepare submissions under IVDR EU regulations. These efforts aim to secure the necessary CE marking for the EU market, paving the way for full-scale commercialization. The following achievements in sales...

Since the summer, Qlife has been working diligently in close collaboration with its partner, Hipro Biotechnology, in China. The company is pleased to share the following updates: 1. Excellent clinical data for Egoo CRP in China 2. Additional biomarkers are advancing to the clinical testing phase 3. Hipro is preparing the production setup for the Egoo Analyzer ahead of market launch in China Excellent clinical data for CRP in China. Qlife's strategic partner in China, Hipro Biotechnology, has successfully completed an initial clinical study with excellent results. The final...